

Potential High Cost Claimants

Group: J0653 - Peo Pro Services

Initial Review Period = Paid: 04/01/2021 - 03/31/2022

Final Review Period = Incurred: 04/01/2019 - 03/31/2022

Captures members with medical claims in excess of \$2,500 OR pharmacy claims in excess of \$5,000 in the latest 12/15



Notes: (See Codes Below)

1 = Specialty Drug Indicator

2 = Treatment Month <=3 AND Total Charged >=\$100,000

3 = Treatment Month <=12 AND Total Charged >50% of Estimated High

4 = Catastrophic Case - Exceeds Book 90th Percentile For Clinical Classification

MBR #	TOP 3 CLINICAL CLASSIFICATION (Descending by Cost)	START DATE	SPLTY RX	MED \$	CHEMO RAD \$	RX \$	TTL \$	EST HIGH	EST REMAIN	NOTES
1	MELANOMAS OF SKIN, OTHER LIVER DISEASES, THYROID DISORDERS	02/21	N	\$37,257	\$0	\$6,266	\$43,523	\$1,186,825	\$1,143,302	
37	ENCEPHALITIS (EXCEPT THAT CAUSED BY TUBERCULOSIS OR SEXUALLY TRANSMITTED DISEASE), OTHER NERVOUS SYSTEM DISORDERS, OTHER ACQUIRED DEFORMITIES	02/21	N	\$10,393	\$0	\$0	\$10,393	\$1,004,138	\$993,744	
11	CARDIAC AND CIRCULATORY CONGENITAL ANOMALIES, OTHER GASTROINTESTINAL DISORDERS, GASTROINTESTINAL AGENTS	02/21	N	\$2,980	\$0	\$185	\$3,165	\$709,409	\$706,244	
4	NEOPLASMS OF UNSPECIFIED NATURE OR UNCERTAIN BEHAVIOR, ENDOMETRIOSIS, OTHER ENDOCRINE DISORDERS	12/21	N	\$52,861	\$0	\$282	\$53,143	\$675,184	\$622,041	
20	PERI; ENDO; AND MYOCARDITIS; CARDIOMYOPATHY (EXCEPT THAT CAUSED BY TUBERCULOSIS OR SEXUALLY TRANSMITTED DISEASE), OTHER BONE DISEASE AND MUSCULOSKELETAL DEFORMITIES, OTHER CONNECTIVE TISSUE DISEASE	04/21	N	\$9,966	\$0	\$587	\$10,553	\$556,920	\$546,367	
36	CANCER OF ESOPHAGUS, ESOPHAGEAL DISORDERS, PLEURISY; PNEUMOTHORAX; PULMONARY COLLAPSE	03/21	N	\$223,567	\$0	\$555	\$224,122	\$743,591	\$519,469	
51	SPONDYLOSIS; INTERVERTEBRAL DISC DISORDERS; OTHER BACK PROBLEMS, OTHER ACQUIRED DEFORMITIES, NEUROMUSCULAR DRUGS	06/20	N	\$6,160	\$0	\$1,216	\$7,376	\$427,733	\$420,357	
31	SPONDYLOSIS; INTERVERTEBRAL DISC DISORDERS; OTHER BACK PROBLEMS, OTHER NERVOUS SYSTEM DISORDERS, CENTRAL NERVOUS SYSTEM DRUGS	03/22	N	\$13,325	\$0	\$119	\$13,444	\$427,733	\$414,289	
7	EPILEPSY; CONVULSIONS, OTHER NERVOUS SYSTEM DISORDERS, OTHER AND UNSPECIFIED BENIGN NEOPLASM	09/21	N	\$20,181	\$0	\$592	\$20,773	\$433,735	\$412,962	
30	EPILEPSY; CONVULSIONS, TOPICAL PRODUCTS	04/21	N	\$20,441	\$0	\$374	\$20,815	\$433,735	\$412,920	
53	SPONDYLOSIS; INTERVERTEBRAL DISC DISORDERS; OTHER BACK PROBLEMS, OTHER NERVOUS SYSTEM DISORDERS, OTHER MALE GENITAL DISORDERS	12/19	N	\$21,620	\$0	\$532	\$22,152	\$427,733	\$405,581	
43	SPONDYLOSIS; INTERVERTEBRAL DISC DISORDERS; OTHER BACK PROBLEMS, OTHER NERVOUS SYSTEM DISORDERS, OTHER MALE GENITAL DISORDERS	10/21	N	\$27,322	\$0	\$227	\$27,549	\$427,733	\$400,183	

Est. cost ranges are calculated using Florida Blue members. Client specific claims in excess of defined thresholds in the latest 12 paid months are retroactively analyzed and compared to book members with similar claims to gauge potential costs.

Potential High Cost Claimants

Group: J0653 - Peo Pro Services

Initial Review Period = Paid: 04/01/2021 - 03/31/2022

Final Review Period = Incurred: 04/01/2019 - 03/31/2022

Captures members with medical claims in excess of \$2,500 OR pharmacy claims in excess of \$5,000 in the latest 12/15



Notes: (See Codes Below)

1 = Specialty Drug Indicator

2 = Treatment Month <=3 AND Total Charged >=\$100,000

3 = Treatment Month <=12 AND Total Charged >50% of Estimated High

4 = Catastrophic Case - Exceeds Book 90th Percentile For Clinical Classification

MBR #	TOP 3 CLINICAL CLASSIFICATION (Descending by Cost)	START DATE	SPLTY RX	MED \$	CHEMO RAD \$	RX \$	TTL \$	EST HIGH	EST REMAIN	NOTES
17	SPONDYLOSIS; INTERVERTEBRAL DISC DISORDERS; OTHER BACK PROBLEMS, CARDIAC DYSRHYTHMIAS, CENTRAL NERVOUS SYSTEM DRUGS	04/21	N	\$21,171	\$0	\$16,523	\$37,693	\$427,733	\$390,039	
9	SPONDYLOSIS; INTERVERTEBRAL DISC DISORDERS; OTHER BACK PROBLEMS, OTHER BONE DISEASE AND MUSCULOSKELETAL DEFORMITIES, OTHER CONNECTIVE TISSUE DISEASE	04/21	N	\$47,049	\$0	\$1,643	\$48,692	\$427,733	\$379,041	
5	ANALGESIC & ANESTHETICS W/SPECIALTY, RHEUMATOID ARTHRITIS AND RELATED DISEASE, ANTIINFECTIVE AGENTS	12/21	Y	\$163	\$0	\$34,149	\$34,312	\$393,268	\$358,956	1
48	SPONDYLOSIS; INTERVERTEBRAL DISC DISORDERS; OTHER BACK PROBLEMS, MISCELLANEOUS MENTAL HEALTH DISORDERS, CARDIOVASCULAR AGENTS	10/20	N	\$69,308	\$0	\$5,713	\$75,021	\$427,733	\$352,712	
24	ANALGESIC & ANESTHETICS W/SPECIALTY, ENDOCRINE/METABOLIC DRUGS, CENTRAL NERVOUS SYSTEM DRUGS	12/21	Y	\$219	\$0	\$46,897	\$47,116	\$393,268	\$346,152	1
12	SPONDYLOSIS; INTERVERTEBRAL DISC DISORDERS; OTHER BACK PROBLEMS, NEUROMUSCULAR DRUGS, ANALGESIC & ANESTHETICS	06/21	N	\$89,594	\$0	\$106	\$89,700	\$427,733	\$338,033	
59	OTHER BONE DISEASE AND MUSCULOSKELETAL DEFORMITIES, OTHER NERVOUS SYSTEM DISORDERS, OTHER CONNECTIVE TISSUE DISEASE	10/21	N	\$3,661	\$0	\$0	\$3,661	\$337,779	\$334,118	
61	OTHER BONE DISEASE AND MUSCULOSKELETAL DEFORMITIES, OTHER UPPER RESPIRATORY INFECTIONS, ANTIINFECTIVE AGENTS	01/20	N	\$4,630	\$0	\$134	\$4,764	\$337,779	\$333,015	
15	OTHER NUTRITIONAL; ENDOCRINE; AND METABOLIC DISORDERS, OTHER CONNECTIVE TISSUE DISEASE, CENTRAL NERVOUS SYSTEM DRUGS	03/20	N	\$11,793	\$0	\$3,396	\$15,190	\$331,162	\$315,973	
56	CARDIAC DYSRHYTHMIAS, HEMATOLOGICAL AGENTS, CARDIOVASCULAR AGENTS	03/21	N	\$154,448	\$0	\$1,243	\$155,691	\$470,598	\$314,907	
26	PLEURISY; PNEUMOTHORAX; PULMONARY COLLAPSE, OTHER LOWER RESPIRATORY DISEASE, CONGESTIVE HEART FAILURE; NONHYPERTENSIVE	02/22	N	\$36,901	\$0	\$178	\$37,079	\$309,818	\$272,739	
10	OTHER AND UNSPECIFIED BENIGN NEOPLASM, OTHER GASTROINTESTINAL DISORDERS, DIABETES MELLITUS WITHOUT COMPLICATION	02/22	N	\$3,620	\$0	\$616	\$4,236	\$271,160	\$266,924	

Est. cost ranges are calculated using Florida Blue members. Client specific claims in excess of defined thresholds in the latest 12 paid months are retroactively analyzed and compared to book members with similar claims to gauge potential costs.

Potential High Cost Claimants

Group: J0653 - Peo Pro Services

Initial Review Period = Paid: 04/01/2021 - 03/31/2022

Final Review Period = Incurred: 04/01/2019 - 03/31/2022

Captures members with medical claims in excess of \$2,500 OR pharmacy claims in excess of \$5,000 in the latest 12/15



Notes: (See Codes Below)

1 = Specialty Drug Indicator

2 = Treatment Month <=3 AND Total Charged >=\$100,000

3 = Treatment Month <=12 AND Total Charged >50% of Estimated High

4 = Catastrophic Case - Exceeds Book 90th Percentile For Clinical Classification

MBR #	TOP 3 CLINICAL CLASSIFICATION (Descending by Cost)	START DATE	SPLTY RX	MED \$	CHEMO RAD \$	RX \$	TTL \$	EST HIGH	EST REMAIN	NOTES
28	OTHER GASTROINTESTINAL DISORDERS, OTHER MALE GENITAL DISORDERS, OTHER CONNECTIVE TISSUE DISEASE	06/21	N	\$20,521	\$0	\$20	\$20,541	\$283,872	\$263,331	
18	OTHER GASTROINTESTINAL DISORDERS, OTHER NONTRAUMATIC JOINT DISORDERS, OTHER CONNECTIVE TISSUE DISEASE	04/21	N	\$22,391	\$0	\$95	\$22,486	\$283,872	\$261,386	
41	OTHER LOWER RESPIRATORY DISEASE, NONINFECTIOUS GASTROENTERITIS, OTHER UPPER RESPIRATORY DISEASE	03/20	N	\$5,152	\$0	\$373	\$5,525	\$266,894	\$261,369	
58	OTHER LOWER RESPIRATORY DISEASE, OTHER ENDOCRINE DISORDERS, CARDIAC DYSRHYTHMIAS	12/20	N	\$15,010	\$0	\$230	\$15,240	\$266,894	\$251,654	
29	OTHER AND UNSPECIFIED BENIGN NEOPLASM, GASTROINTESTINAL AGENTS, RESPIRATORY AGENTS	09/21	N	\$22,420	\$0	\$1,921	\$24,341	\$271,160	\$246,818	
46	OTHER GASTROINTESTINAL DISORDERS, INFLAMMATORY DISEASES OF FEMALE PELVIC ORGANS, OTHER UPPER RESPIRATORY INFECTIONS	04/21	N	\$39,511	\$0	\$857	\$40,367	\$283,872	\$243,505	
2	OTHER MALE GENITAL DISORDERS, GENITOURINARY SYMPTOMS AND ILLDEFINED CONDITIONS	03/22	N	\$11,041	\$0	\$0	\$11,041	\$225,637	\$214,596	
57	SKIN AND SUBCUTANEOUS TISSUE INFECTIONS, OTHER ACQUIRED DEFORMITIES, TOPICAL PRODUCTS	10/21	N	\$14,592	\$0	\$82	\$14,674	\$227,358	\$212,684	
40	THYROID DISORDERS, OTHER NONTRAUMATIC JOINT DISORDERS, ENDOCRINE/METABOLIC DRUGS	02/20	N	\$4,018	\$0	\$696	\$4,714	\$211,416	\$206,702	
23	CANCER OF THYROID, THYROID DISORDERS, OTHER AND UNSPECIFIED BENIGN NEOPLASM	09/20	N	\$59,859	\$0	\$320	\$60,179	\$244,318	\$184,139	
55	OTHER CONNECTIVE TISSUE DISEASE, CENTRAL NERVOUS SYSTEM DRUGS, SKIN AND SUBCUTANEOUS TISSUE INFECTIONS	11/21	N	\$18,344	\$0	\$672	\$19,016	\$194,439	\$175,423	
35	OTHER UPPER RESPIRATORY INFECTIONS, OTHER NERVOUS SYSTEM DISORDERS, CENTRAL NERVOUS SYSTEM DRUGS	01/20	N	\$22,586	\$0	\$2,075	\$24,661	\$197,090	\$172,429	
50	OTHER AND ILLDEFINED HEART DISEASE, DIABETES MELLITUS WITHOUT COMPLICATION, BIOLOGICALS	09/20	N	\$2,746	\$0	\$117	\$2,863	\$168,204	\$165,340	
21	ANTIINFECTIVE AGENTS, OTHER UPPER RESPIRATORY INFECTIONS, HIV INFECTION	09/21	N	\$10,884	\$0	\$33,437	\$44,322	\$209,637	\$165,315	
22	OTHER UPPER RESPIRATORY INFECTIONS, INFLAMMATORY DISEASES OF FEMALE PELVIC ORGANS, OTHER NONTRAUMATIC JOINT DISORDERS	12/19	N	\$32,403	\$0	\$355	\$32,758	\$197,090	\$164,331	

Est. cost ranges are calculated using Florida Blue members. Client specific claims in excess of defined thresholds in the latest 12 paid months are retroactively analyzed and compared to book members with similar claims to gauge potential costs.

Potential High Cost Claimants



Group: J0653 - Peo Pro Services

Initial Review Period = Paid: 04/01/2021 - 03/31/2022

Final Review Period = Incurred: 04/01/2019 - 03/31/2022

Captures members with medical claims in excess of \$2,500 OR pharmacy claims in excess of \$5,000 in the latest 12/15

Notes: (See Codes Below)

1 = Specialty Drug Indicator

2 = Treatment Month <=3 AND Total Charged >=\$100,000

3 = Treatment Month <=12 AND Total Charged >50% of Estimated High

4 = Catastrophic Case - Exceeds Book 90th Percentile For Clinical Classification

MBR #	TOP 3 CLINICAL CLASSIFICATION (Descending by Cost)	START DATE	SPLTY RX	MED \$	CHEMO RAD \$	RX \$	TTL \$	EST HIGH	EST REMAIN	NOTES
62	OTHER NONTRAUMATIC JOINT DISORDERS, OTHER SKIN DISORDERS, OTHER CONNECTIVE TISSUE DISEASE	06/20	N	\$5,378	\$0	\$56	\$5,434	\$168,929	\$163,495	
60	OTHER NONTRAUMATIC JOINT DISORDERS, CENTRAL NERVOUS SYSTEM DRUGS, ENDOCRINE/METABOLIC DRUGS	05/21	N	\$5,531	\$0	\$2,060	\$7,591	\$168,929	\$161,338	
3	ESOPHAGEAL DISORDERS, OTHER GASTROINTESTINAL DISORDERS, OTHER DISORDERS OF STOMACH AND DUODENUM	01/22	N	\$8,548	\$0	\$258	\$8,806	\$162,929	\$154,123	
45	ANALGESIC & ANESTHETICS W/SPECIALTY, CARDIOVASCULAR AGENTS, SPONDYLOSIS; INTERVERTEBRAL DISC DISORDERS; OTHER BACK PROBLEMS	12/19	Y	\$6,478	\$0	\$240,529	\$247,007	\$393,268	\$146,261	1
52	OTHER CONNECTIVE TISSUE DISEASE, OTHER NONTRAUMATIC JOINT DISORDERS, SPONDYLOSIS; INTERVERTEBRAL DISC DISORDERS; OTHER BACK PROBLEMS	06/20	N	\$48,242	\$0	\$247	\$48,489	\$194,439	\$145,950	
25	ANTIINFECTIVE AGENTS, HIV INFECTION, GASTROINTESTINAL AGENTS	02/21	N	\$6,816	\$0	\$61,672	\$68,488	\$209,637	\$141,149	
44	OTHER FEMALE GENITAL DISORDERS	02/22	N	\$11,768	\$0	\$0	\$11,768	\$150,090	\$138,322	
34	OTHER SKIN DISORDERS, MISCELLANEOUS MENTAL HEALTH DISORDERS, CENTRAL NERVOUS SYSTEM DRUGS	05/21	N	\$2,747	\$0	\$475	\$3,222	\$139,830	\$136,608	
27	OTHER SKIN DISORDERS	01/22	N	\$4,205	\$0	\$0	\$4,205	\$139,830	\$135,625	
8	CENTRAL NERVOUS SYSTEM DRUGS, BIOLOGICALS, TOPICAL PRODUCTS	05/20	N	\$0	\$0	\$6,611	\$6,611	\$129,577	\$122,966	
19	CENTRAL NERVOUS SYSTEM DRUGS, OTHER BONE DISEASE AND MUSCULOSKELETAL DEFORMITIES, GENITOURINARY PRODUCTS	12/20	N	\$2,681	\$0	\$5,242	\$7,923	\$129,577	\$121,653	
6	GASTROINTESTINAL AGENTS, OTHER UPPER RESPIRATORY DISEASE, CENTRAL NERVOUS SYSTEM DRUGS	08/21	N	\$1,746	\$0	\$8,828	\$10,574	\$127,515	\$116,941	
49	CENTRAL NERVOUS SYSTEM DRUGS, OTHER NONTRAUMATIC JOINT DISORDERS, SPONDYLOSIS; INTERVERTEBRAL DISC DISORDERS; OTHER BACK PROBLEMS	01/20	N	\$3,263	\$0	\$14,340	\$17,603	\$129,577	\$111,974	
38	ANTIINFECTIVE AGENTS, RESPIRATORY AGENTS, HIV INFECTION	12/19	N	\$1,012	\$0	\$106,743	\$107,755	\$209,637	\$101,882	
42	ANALGESIC & ANESTHETICS W/SPECIALTY, TOPICAL PRODUCTS, OTHER INFLAMMATORY CONDITION OF SKIN	12/19	Y	\$1,429	\$0	\$297,793	\$299,222	\$393,268	\$94,046	1
32	ENDOCRINE/METABOLIC DRUGS, OSTEOARTHRITIS, RESPIRATORY AGENTS	06/21	N	\$3,563	\$0	\$14,768	\$18,331	\$112,254	\$93,924	

Est. cost ranges are calculated using Florida Blue members. Client specific claims in excess of defined thresholds in the latest 12 paid months are retroactively analyzed and compared to book members with similar claims to gauge potential costs.

Potential High Cost Claimants

Group: J0653 - Peo Pro Services

Initial Review Period = Paid: 04/01/2021 - 03/31/2022

Final Review Period = Incurred: 04/01/2019 - 03/31/2022

Captures members with medical claims in excess of \$2,500 OR pharmacy claims in excess of \$5,000 in the latest 12/15



Notes: (See Codes Below)

1 = Specialty Drug Indicator

2 = Treatment Month <=3 AND Total Charged >=\$100,000

3 = Treatment Month <=12 AND Total Charged >50% of Estimated High

4 = Catastrophic Case - Exceeds Book 90th Percentile For Clinical Classification

MBR #	TOP 3 CLINICAL CLASSIFICATION (Descending by Cost)	START DATE	SPLTY RX	MED \$	CHEMO RAD \$	RX \$	TTL \$	EST HIGH	EST REMAIN	NOTES
13	RESPIRATORY AGENTS, OTHER UPPER RESPIRATORY INFECTIONS, SPONDYLOSIS; INTERVERTEBRAL DISC DISORDERS; OTHER BACK PROBLEMS	04/20	N	\$8,778	\$0	\$5,949	\$14,727	\$102,101	\$87,375	
39	RESPIRATORY AGENTS, CENTRAL NERVOUS SYSTEM DRUGS, ENDOCRINE/METABOLIC DRUGS	12/19	N	\$0	\$0	\$17,012	\$17,012	\$102,101	\$85,089	
54	HEMATOLOGICAL AGENTS, SPONDYLOSIS; INTERVERTEBRAL DISC DISORDERS; OTHER BACK PROBLEMS, ENDOCRINE/METABOLIC DRUGS	01/21	N	\$2,497	\$0	\$5,675	\$8,172	\$91,114	\$82,942	
33	ENDOCRINE/METABOLIC DRUGS, OTHER UPPER RESPIRATORY DISEASE, OTHER UPPER RESPIRATORY INFECTIONS	06/21	N	\$37,207	\$0	\$17,528	\$54,735	\$112,254	\$57,519	
16	CENTRAL NERVOUS SYSTEM DRUGS, CORONARY ATHEROSCLEROSIS AND OTHER HEART DISEASE, CARDIOVASCULAR AGENTS	02/20	N	\$32,413	\$0	\$40,157	\$72,570	\$129,577	\$57,007	
14	BENIGN NEOPLASM OF UTERUS, CARDIAC DYSRHYTHMIAS, NEOPLASMS OF UNSPECIFIED NATURE OR UNCERTAIN BEHAVIOR	09/21	N	\$163,257	\$0	\$1,106	\$164,362	\$194,410	\$30,048	
47	PULMONARY HEART DISEASE, OTHER LOWER RESPIRATORY DISEASE, HEMATOLOGICAL AGENTS	07/20	N	\$325,819	\$0	\$10,843	\$336,662	\$337,513	\$851	

Est. cost ranges are calculated using Florida Blue members. Client specific claims in excess of defined thresholds in the latest 12 paid months are retroactively analyzed and compared to book members with similar claims to gauge potential costs.